850 related articles for article (PubMed ID: 33774649)
1. Cathepsin L plays a key role in SARS-CoV-2 infection in humans and humanized mice and is a promising target for new drug development.
Zhao MM; Yang WL; Yang FY; Zhang L; Huang WJ; Hou W; Fan CF; Jin RH; Feng YM; Wang YC; Yang JK
Signal Transduct Target Ther; 2021 Mar; 6(1):134. PubMed ID: 33774649
[TBL] [Abstract][Full Text] [Related]
2. In silico study of azithromycin, chloroquine and hydroxychloroquine and their potential mechanisms of action against SARS-CoV-2 infection.
Braz HLB; Silveira JAM; Marinho AD; de Moraes MEA; Moraes Filho MO; Monteiro HSA; Jorge RJB
Int J Antimicrob Agents; 2020 Sep; 56(3):106119. PubMed ID: 32738306
[TBL] [Abstract][Full Text] [Related]
3. An Updated Review on Betacoronavirus Viral Entry Inhibitors: Learning from Past Discoveries to Advance COVID-19 Drug Discovery.
Sabbah DA; Hajjo R; Bardaweel SK; Zhong HA
Curr Top Med Chem; 2021; 21(7):571-596. PubMed ID: 33463470
[TBL] [Abstract][Full Text] [Related]
4. Amantadine disrupts lysosomal gene expression: A hypothesis for COVID19 treatment.
Smieszek SP; Przychodzen BP; Polymeropoulos MH
Int J Antimicrob Agents; 2020 Jun; 55(6):106004. PubMed ID: 32361028
[TBL] [Abstract][Full Text] [Related]
5. Omicsynin B4 potently blocks coronavirus infection by inhibiting host proteases cathepsin L and TMPRSS2.
Li Y; Wang K; Sun H; Wu S; Wang H; Shi Y; Li X; Yan H; Yang G; Wu M; Li Y; Ding X; Si S; Jiang J; Du Y; Li Y; Hong B
Antiviral Res; 2023 Jun; 214():105606. PubMed ID: 37076089
[TBL] [Abstract][Full Text] [Related]
6. Olgotrelvir, a dual inhibitor of SARS-CoV-2 M
Mao L; Shaabani N; Zhang X; Jin C; Xu W; Argent C; Kushnareva Y; Powers C; Stegman K; Liu J; Xie H; Xu C; Bao Y; Xu L; Zhang Y; Yang H; Qian S; Hu Y; Shao J; Zhang C; Li T; Li Y; Liu N; Lin Z; Wang S; Wang C; Shen W; Lin Y; Shu D; Zhu Z; Kotoi O; Kerwin L; Han Q; Chumakova L; Teijaro J; Royal M; Brunswick M; Allen R; Ji H; Lu H; Xu X
Med; 2024 Jan; 5(1):42-61.e23. PubMed ID: 38181791
[TBL] [Abstract][Full Text] [Related]
7. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
Mellott DM; Tseng CT; Drelich A; Fajtová P; Chenna BC; Kostomiris DH; Hsu J; Zhu J; Taylor ZW; Kocurek KI; Tat V; Katzfuss A; Li L; Giardini MA; Skinner D; Hirata K; Yoon MC; Beck S; Carlin AF; Clark AE; Beretta L; Maneval D; Hook V; Frueh F; Hurst BL; Wang H; Raushel FM; O'Donoghue AJ; de Siqueira-Neto JL; Meek TD; McKerrow JH
ACS Chem Biol; 2021 Apr; 16(4):642-650. PubMed ID: 33787221
[TBL] [Abstract][Full Text] [Related]
8. Identification of potent small molecule inhibitors of SARS-CoV-2 entry.
Mediouni S; Mou H; Otsuka Y; Jablonski JA; Adcock RS; Batra L; Chung DH; Rood C; de Vera IMS; Rahaim R; Ullah S; Yu X; Getmanenko YA; Kennedy NM; Wang C; Nguyen TT; Hull M; Chen E; Bannister TD; Baillargeon P; Scampavia L; Farzan M; Valente ST; Spicer TP
SLAS Discov; 2022 Jan; 27(1):8-19. PubMed ID: 35058179
[TBL] [Abstract][Full Text] [Related]
9. Withanone from
Balkrishna A; Pokhrel S; Singh H; Joshi M; Mulay VP; Haldar S; Varshney A
Drug Des Devel Ther; 2021; 15():1111-1133. PubMed ID: 33737804
[TBL] [Abstract][Full Text] [Related]
10. Cathepsin L in COVID-19: From Pharmacological Evidences to Genetics.
Gomes CP; Fernandes DE; Casimiro F; da Mata GF; Passos MT; Varela P; Mastroianni-Kirsztajn G; Pesquero JB
Front Cell Infect Microbiol; 2020; 10():589505. PubMed ID: 33364201
[TBL] [Abstract][Full Text] [Related]
11. Nanoengineered Red Blood Cells Loaded with TMPRSS2 and Cathepsin L Inhibitors Block SARS-CoV-2 Pseudovirus Entry into Lung ACE2
Yang H; Zhou JN; Zhang XM; Ling DD; Sun YB; Li CY; Zhou QQ; Shi GN; Wang SH; Lin XS; Fan T; Wang HY; Zeng Q; Jia YL; Xi JF; Jin YG; Pei XT; Yue W
Adv Mater; 2024 Apr; 36(15):e2310306. PubMed ID: 38194699
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
Zahradník J; Marciano S; Shemesh M; Zoler E; Harari D; Chiaravalli J; Meyer B; Rudich Y; Li C; Marton I; Dym O; Elad N; Lewis MG; Andersen H; Gagne M; Seder RA; Douek DC; Schreiber G
Nat Microbiol; 2021 Sep; 6(9):1188-1198. PubMed ID: 34400835
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of ACE2-Spike Interaction by an ACE2 Binder Suppresses SARS-CoV-2 Entry.
Shin YH; Jeong K; Lee J; Lee HJ; Yim J; Kim J; Kim S; Park SB
Angew Chem Int Ed Engl; 2022 Mar; 61(11):e202115695. PubMed ID: 35043545
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous Inhibition of SARS-CoV-2 Entry Pathways by Cyclosporine.
Prasad K; Ahamad S; Kanipakam H; Gupta D; Kumar V
ACS Chem Neurosci; 2021 Mar; 12(5):930-944. PubMed ID: 33606519
[TBL] [Abstract][Full Text] [Related]
15. Identification of SARS-CoV-2 Receptor Binding Inhibitors by In Vitro Screening of Drug Libraries.
David AB; Diamant E; Dor E; Barnea A; Natan N; Levin L; Chapman S; Mimran LC; Epstein E; Zichel R; Torgeman A
Molecules; 2021 May; 26(11):. PubMed ID: 34072087
[TBL] [Abstract][Full Text] [Related]
16. A second functional furin site in the SARS-CoV-2 spike protein.
Zhang Y; Zhang L; Wu J; Yu Y; Liu S; Li T; Li Q; Ding R; Wang H; Nie J; Cui Z; Wang Y; Huang W; Wang Y
Emerg Microbes Infect; 2022 Dec; 11(1):182-194. PubMed ID: 34856891
[TBL] [Abstract][Full Text] [Related]
17. Potent Anti-SARS-CoV-2 Activity by the Natural Product Gallinamide A and Analogues via Inhibition of Cathepsin L.
Ashhurst AS; Tang AH; Fajtová P; Yoon MC; Aggarwal A; Bedding MJ; Stoye A; Beretta L; Pwee D; Drelich A; Skinner D; Li L; Meek TD; McKerrow JH; Hook V; Tseng CT; Larance M; Turville S; Gerwick WH; O'Donoghue AJ; Payne RJ
J Med Chem; 2022 Feb; 65(4):2956-2970. PubMed ID: 34730959
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 receptor and malignant cancers: Association of
Zhang L; Wei C; Li D; He J; Liu S; Deng H; Cheng J; Du J; Liu X; Chen H; Sun S; Yu H; Fu J
Int J Biol Sci; 2022; 18(6):2362-2371. PubMed ID: 35414771
[TBL] [Abstract][Full Text] [Related]
19. Repositioning of histamine H
Ge S; Wang X; Hou Y; Lv Y; Wang C; He H
Eur J Pharmacol; 2021 Apr; 896():173897. PubMed ID: 33497607
[TBL] [Abstract][Full Text] [Related]
20. Potential therapeutic approaches for the early entry of SARS-CoV-2 by interrupting the interaction between the spike protein on SARS-CoV-2 and angiotensin-converting enzyme 2 (ACE2).
Xiang Y; Wang M; Chen H; Chen L
Biochem Pharmacol; 2021 Oct; 192():114724. PubMed ID: 34371003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
